Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $33.3500 (-4.93%) ($33.2600 - $36.1700) on Wed. Dec. 13, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.48% (three month average) | RSI | 52 | Latest Price | $33.3500(-4.93%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.7% a day on average for past five trading days. | Weekly Trend | ADMS advances 1.8% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(27%) IBB(24%) IWM(19%) IWO(19%) QQQ(19%) | Factors Impacting ADMS price | ADMS will decline at least -2.24% in a week (0% probabilities). VIXM(-13%) BNDX(-9%) UUP(-8%) UNG(-7%) TLT(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.24% (StdDev 4.48%) | Hourly BBV | 0 () | Intraday Trend | -4.9% | | | |
|
Resistance Level | $33.42 | 5 Day Moving Average | $35.24(-5.36%) | 10 Day Moving Average | $35.22(-5.31%) | 20 Day Moving Average | $33.42(-0.21%) | To recent high | -10.2% | To recent low | 83.9% | Market Cap | $943m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |